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CASE REPORT 
Leprosy in Malta: not to be forgotten   
Monique Cachia, Alicia Dimech, Alexandra Betts, Charles Mallia Azzopardi, Michael J Boffa
Leprosy is a granulomatous infection that was considered endemic in 
Malta up until being declared eradicated in 1999 thanks to the Malta 
Leprosy Eradication Programme. However, leprosy remains endemic 
in a number of low-to-middle income countries, and may be imported 
to non-endemic regions like Malta by migrants.  We report a case of 
a man from the Philippines  presenting with nodular lesions over the 
face, trunk and limbs and a hypoaesthetic patch over the arm. A skin 
biopsy supported the clinical suspicion of midline 
borderline/borderline lepromatous leprosy and triple therapy with 
clofazimine, dapsone and rifampicin was initiated. Despite having a 
wide clinical differential diagnosis, leprosy must always be kept in 
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INTRODUCTION 
Leprosy is a chronic, progressive, 
granulomatous infection caused by 
Mycobacterium leprae. In Malta, this disease 
was once endemic but after the Leprosy 
Eradication Programme which started in 1972, 
no endemic cases have been reported since its 
termination in 1999.1 However, in countries 
where the disease is still endemic the 
incidence remains relatively stable, possibly 
since many cases go unrecognised and 
therefore undiagnosed.2 In view of its long 
incubation period, travelers from endemic 
countries may develop symptoms after 
migration. We present a case of a man from the 
Philippines residing in Malta, diagnosed with 
midline borderline/ borderline lepromatous 
leprosy.  
CASE PRESENTATION 
A 29-year-old man from the Philippines 
presented with a 4-year history of an enlarging 
erythematous patch over the outer aspect of 
the right arm (Figure 1) and a 6-month history 
of erythematous-to-brown nodular lesions 
over the face, trunk and limbs (Figures 2A and 
2B). He reported numbness and reduced 
sweating over the right arm patch but all other 
lesions were asymptomatic. He was previously 
healthy, had moved to Malta from the 
Philippines 20 months previously and was 
residing with his partner who was 
asymptomatic. On examination there was a 
12cm x 12cm annular erythematous patch with 
a hypopigmented centre on the right arm 
(Figure 1) The lesion had raised borders with 
palpable cord-like structures at one end and 
reduced sensation to cotton wool and pinprick. 
All other lesions appeared to have normal 
sensation. Incisional biopsies from the right 
arm, right cheek and left thigh showed 
granulomatous inflammation with sheets and 
nodules of foamy epithelioid histiocytes, 
lymphocytes and occasional plasma cells 
extending perineurally (Figures 3A and 3B). A 
Wade-Fite stain revealed moderate numbers 
of acid-fast bacilli within the cytoplasm of a 
minority of the histiocytes (Figure 3C). Based 
on the clinical and histological findings a 
diagnosis of tuberculoid/borderline 
tuberculoid leprosy recently downgrading to 
borderline lepromatous leprosy was made. 
Treatment with dapsone 100mg daily, 
rifampicin 600mg daily and clofazimine 50mg 
daily was started, for an expected duration of 
24 months. A few weeks into treatment a 
widespread non-itchy, erythematous maculo-
papular eruption, consistent with a Type 1 
reversal reaction, appeared and was treated 
with one dose of intramuscular 
methylprednisolone acetate 80mg. Following 
improvement of these symptoms the patient 
decided to return to the Philippines. He was 
given written confirmation of his diagnosis and 
was strongly advised to seek medical attention 
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Figure 1 Well-demarcated anaesthetic patch with an erythematous border and central 
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Figure 3A  Low power view showing perineural granulomatous inflammation. H&E stain. Original  
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Figure 3B  Medium power view showing non-necrotising granulomatous infiltrate composed of  
  sheets of epithelioid histiocytes with abundant foamy cytoplasm and scattered  















Figure 3C  High Power view showing occasional clusters of acid-fast bacilli. Wade-Fite stain. 















Malta Medical Journal     Volume 33 Issue 01 2021           
DISCUSSION  
Leprosy is a chronic and still-feared infectious 
disease. Early diagnosis and treatment are 
essential to help prevent the physical disability 
and psychological sequalae associated with 
this disfiguring disease.3 
The clinical manifestations are varied and can 
include hypopigmented, erythematous or 
scaly macules, patches, plaques and nodules. 
These features depend on the host’s cellular 
immune response to the causative organism 
and predominantly affect the skin and 
peripheral nerves. Because of its varied clinical 
presentation leprosy can mimic several skin 
conditions including granuloma annulare, 
tinea corporis, annular psoriasis, lupus 
erythematosus, cutaneous leishmaniasis and 
mycosis fungoides. Diagnosis of leprosy may 
be particularly challenging in pigmented skin 
and a key distinguishing feature of lesions is 
impaired sensation.4 
There are two main classifications of leprosy 
(Tables 1 and 2).5-6 The Ridley-Jopling 
classification categorises leprosy in five 
groups, based on cutaneous, neurological, 
histopathological and immunological 
features.5 The World Health Organisation 
(WHO) classification is simpler and is based on 
the number of skin lesions and bacilli on skin 
smear.7 
 
Table 1 Ridley-Jopling classification.4,6 
 Ridley-Jopling classification 
Observation / 
Test  
Type of leprosy 
TT BT BB BL LL 
No. of lesions Single usually Single or few Numerous (+) Numerous (++) Numerous (+++) 


















Not affected or 
minimally 
affected 
Hair growth in 
lesions 







AFB in lesions  Nil Nil or scanty Moderate 
numbers 
Numerous (+) Numerous with 
globi (++) 
AFB in nasal 
scraping or in 
blows 
Nil Nil  Nil  Usually nil Numerous with 
globi (++) 





Negative  Negative Negative 
AFB: Acid fast bacilli, TT: polar tuberculoid, BT: Borderline tuberculoid, BB: Mid-borderline, BL: Borderline 
lepromatous, LL: Polar lepromatous 
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Table 2  WHO Classification.5 
                                           
WHO Classification 
Paucibacillary Leprosy Multibacillary Leprosy 
 
5 or fewer skin lesions without detectable 
bacilli on skin smear 
6 or more skin lesions and may have 
detectable bacilli on skin smear 
 
Our patient had a single long-standing 
hypoaesthetic lesion on his right arm 
suggestive of tuberculoid/borderline 
tuberculoid leprosy. The new infiltrated 
lesions on the face, trunk and limbs were in 
keeping with progression to borderline 
lepromatous disease, supported by the 
presence of numerous acid-fast bacilli within 
the cytoplasm of the histiocytes on histology.  
Current recommended treatment of 
tuberculoid leprosy is dapsone (100mg daily) 
and rifampicin (600mg daily) for 12 months 
whilst for patients with leprosy at the 
lepromatous end of the spectrum dapsone 
(100mg daily), rifampicin (600mg daily) and 
clofazimine (50mg daily) for 24 months is 
recommended.4 Accordingly, our patient was 
treated with the latter regimen.  
Possible immunologic reactions in leprosy 
patients include type 1, reversal reaction (RR) 
and type 2, erythema nodosum leprosum (ENL) 
and can affect up to half of patients during or 
after completion of treatment.4 RR, as seen in 
this case, manifests as oedema and erythema 
of existing skin lesions in association with 
fever, ulceration and nerve involvement. ENL 
typically presents with acute tender red skin 
nodules, fever and sometimes multiorgan 
involvement   including neuritis, uveitis, 
arthritis, orchitis and hepatosplenomegaly. 4 
In 1972, Malta became the first country 
worldwide to institute a leprosy eradication 
programme with a multidrug therapy regime. 
This consisted of 2 tablets of rifampicin 300mg 
and 2 tablets of isoprodian taken 6 days a week 
for at least 5 months, depending on the clinical 
and bacteriological status of the patient. Each 
isoprodian tablet consisted of 75mg isoniazid, 
75mg prothionamide and 50mg dapsone.1, 8 
Prior to this, standard leprosy treatment 
involved lifelong dapsone monotherapy. In the 
5-year period 1967-1971 prior to initiation of 
this programme the mean annual incidence of 
new cases of Leprosy was 2.7 cases per 
100,000 per year.9 In the programme all known 
leprosy patients (irrespective of their 
bacteriological status) and new patients 
subsequently diagnosed were treated and 
subsequently monitored closely for possible 
relapse. 
The success of this programme led to its 
methodology being implemented by the WHO 
in the mid-1980s in an attempt to eradicate the 
disease on a global scale and multidrug 
therapy has since then become accepted 
worldwide as the standard treatment for 
leprosy. The global prevalence of the disease 
has since diminished drastically from 5.4 
million to a few hundred thousand.10  
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Presently the overwhelming majority of 
leprosy cases are in the developing countries 
of Southeast Asia, South America, Africa, 
Western Pacific and the Eastern 
Mediterranean.10 According to the WHO global 
leprosy update (2019), South-East Asia region 
(SEAR) has contributed to 71% of the new 
leprosy cases worldwide.11 Migration, 
however, can result in patients with leprosy 
presenting anywhere. In the past few years 
Malta has seen an increasing influx of migrants 
and workers from countries where leprosy is 
endemic. For example the number of migrants 
residing in Malta, originating from SEAR 
countries such as the Philippines and India has 
increased by fourfold and ninefold 
respectively between 2014 and 2018.12 
Whereas the Malta Leprosy Eradication Project 
was formally concluded in December 1999   
and Public Health Department records show 
no new cases of leprosy diagnosed in the 
indigenous Maltese population from the year 
2000, new cases have been diagnosed in 
migrants in 2008, 2011 and 2019 (the current 
case).13-14 
 Thus, physicians must be aware of the 
increasing possibility of encountering leprosy, 
and the potential for leprosy to mimic a 
number of conditions. Moreover, although 
infectivity of leprosy is considered to be low, it 
is higher in patients at the lepromatous end of 
the spectrum and thus it is important that 
patients are diagnosed and treated as soon as 
possible. 
CONCLUSION 
This case highlights the importance for 
clinicians in Malta to maintain an index of 
suspicion for non-endemic diseases such as 
leprosy, particularly given the recent rise in 
immigration and ever changing population 
dynamics. 
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